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Abstract: Toll-like receptor 4 (TLR4) contributes to the pathogenesis of coronary ischemia/reperfusion
(IR). To test whether the new TLR4 antagonist, ApTOLL, may prevent coronary IR damage, we
administered 0.078 mg/kg ApTOLL or Placebo in pigs subjected to IR, analyzing the levels of cardiac
troponins, matrix metalloproteinases, pro-, and anti-inflammatory cytokines, heart function, and tissue
integrity over a period of 7 days after IR. Our results show that ApTOLL reduced cardiac troponin-1
24 h after administration, improving heart function, as detected by a significant recovery of the left
ventricle ejection fraction (LVEF) and the shortening fraction (FS) cardiac parameters. The extension
of necrotic and fibrotic areas was also reduced, as detected by Evans blue/2,3,5-triphenyltetrazolium
chloride (TTC) staining, Hematoxylin/Eosine, and Masson Trichrome staining of heart sections,
together with a significant reduction in the expression of the extracellular matrix-degrading, matrix
metalloproteinase 9. Finally, the expression of the following cytokines, CCL1, CCL2, MIP1-A-B,
CCL5, CD40L, C5/C5A, CXCL1, CXCL10, CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, INF-g, IL1-a,
ILI-b, IL-1Ra, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL16, IL17-A, IL17- E, IL18, IL21, IL27, IL32,
MIF, SERPIN-E1, TNF-a, and TREM-1, were also assayed, detecting a pronounced decrease of
pro-inflammatory cytokines after 7 days of treatment with ApTOLL. Altogether, our results show
that ApTOLL is a promising new tool for the treatment of acute myocardial infarction (AMI).
Keywords: toll-like receptor 4; ApTOLL; acute myocardial infarction; cytokines; matrix metalloproteinases
1. Introduction
Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide [1].
Following coronary occlusion, ischemia leads to cardiac cell death [2], and, depending on the necrotic
extension, an adverse remodeling can worsen recovery, leading to chronic heart failure (CHF), and hence
impair the patient′s outcome [2].
Cardiac remodeling is a key step that will determine the severity of heart failure. It all starts in
response to an injury sensed by an inflammatory response, which, in the case of AMI, is mediated
by infiltration and activation of several cell types at the foci of inflammation, with the ultimate goal
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of removing dead cells and tissue repair. The process ends with the inflammation resolution phase,
in which resolutive immune cells and fibroblasts promote cell proliferation, angiogenesis, and a
replenishment of dead tissue with a collagen-based scar [3,4].
Among the different sensors of inflammation, toll-like receptors (TLRs) represent a key molecular
link between innate and adaptative responses, mediating tissue injury and inflammation. Toll-like
receptor 4 (TLR4) is a transmembrane signaling protein, which is the major pattern recognition receptor
expressed by several cell types. Besides bacterial lipopolysaccharide, TLR4 recognizes a variety of
ligands, which are released in response to myocardial ischemia/reperfusion, resulting in the activation
of TLR4 inflammatory signaling pathway in the heart, as a mechanism to increase the expression and
nuclear translocation of nuclear factor kappa-B (NF-kappa-B) transcription factor [5], which leads
to the expression of pro-inflammatory cytokines, including TNF-α, interleukin-1β and interleukin-6,
chemokines, the recruitment of lymphocytes, increasing the expression of inducible nitric oxide
synthase and matrix degrading enzymes [6], and leading to the acute-inflammatory phase and a
source of cardiac cell necrosis. While inflammation is a necessary element during the early stage of
remodeling, a prolonged inflammatory response may impair cardiac physiology by promoting left
ventricle dilation and excessive scar formation [7]. Hence, timely control of the inflammatory response
is crucial to prevent the severity of HF.
Several groups have developed different strategies in mice to study the contribution of TLR4
activation in the cardiac function in response to cardiac ischemia/reperfusion (IR) [8–10], and while all
the studies agree on the effect on cardiac necrosis, a disparity of results arise when studying the effect
of TLR4 on cardiac function.
Small non-coding RNAS, including RNA aptamers, have been tested in experimental diagnostic
and therapeutic diseases [11], including myocardial infarction [12]. ApTOLL is a new therapeutic
tool designed to antagonize TLR4. ApTOLL aptamer is a single-stranded oligonucleotide that
recognizes and specifically binds to TLR4 by structural interaction, as described [13]. Once folded
under physiological conditions, aptamers acquire unique three-dimensional structures based on their
nucleotide sequence, conferring target affinity and specificity [14–16]. The protective effect of ApTOLL
was recently reported against experimental strokes, a setting in which TLR4 played a crucial role in the
initiation of ischemic injury [13].
The present study aimed to evaluate the potential therapeutic effect of ApTOLL as a
cardioprotective compound in a porcine model of cardiac IR.
2. Materials and Methods
2.1. Reagents and Equipment
Hematoxylin-eosin (H/E), Trichrome Masson staining reagents, TTC, Evans blue, and fetal bovine
serum were from Sigma (Madrid, Spain). Horseradish peroxidase (HRP)-conjugated anti-mouse
secondary antibody and liquid 3,3′-diaminobenzidine (DAB) substrate were from Dako (Santa Clara,
CA, USA). The anti-Matrix Metalloprotease 9 (MMP-9) antibody and Human Cardiac Troponin 1
Simple-Step ELISA Kit (ab200016) and the Tunel assay kit (ab206386) were from Abcam (Cambridge,
UK); the proteome Profiler Array (ARY005B) was from R&D Systems (Minneapolis, MN, USA); the
ketamine was from Pfizer (New York, NY, USA); the isoflurane was from Abbvie (North Chicago, IL,
USA); the propofol was from Fresenius (Bad Homburg, Germany); the fentanyl was from Kern Pharma
(Madrid, Spain); the diazepam was from Roche (Basel, Switzerland); and the amiodarone was from
Sanofi Aventis (Gentilly, France).
The following is a list of the most common equipment used for this investigation: The 5415R
Refrigerated Centrifuge was from Eppendorf (Hamburg, Germany). The chemiluminescence imaging
system Fusion Solo-S and the image analysis software Fusion-Capt were from Vilber-Lourmat
(Eberhardzell, Germany). The TCS-SP5 Confocal Microscope was from Leica (Wetzlar, Germany).
The microplate reader was from Biotek (Winooski, VT, USA). The NanoDrop One Spectrophotometer
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was from Thermo Scientific (Waltham, MA, USA). Guiding catheters, angioplasty balloons, and catheter
introducers were from Cordis (Miami, FL, USA). Diagnostic and steerable guidewires were from
Boston Scientifics (Malborough, MA, USA). The balloon inflation devices and midazolam were from
B.Braun (Melsungen, Germany).
2.2. Animal Model of Coronary Ischemia/Reperfusion
Animal procedures were performed in the Experimental Surgery Department of the Hospital
Universitario La Paz (Madrid, Spain), as described [17,18]. The investigation conformed to the Guide
for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1985) and the Animal Welfare Ethics Committee and complied with
the EU Directive on experimental animals (63/2010 EU) and related Spanish legislation (RD 53/2013).
PROEX 365-15.
Before experimentation, animals were housed for one week to avoid cardiovascular responses
derived from anxiety associated with the new environment. Prior to experimentation, the animals
underwent a cardiac ultrasound to check for abnormalities of cardiac anatomy and function (Figure S1).
Yorkshire female pigs (37.8 ± 5.2 kg) were pre-medicated with intramuscular ketamine 10 mg/kg
(Pfizer) and midazolam 0.5 mg/kg (B.Braun). Anesthesia was induced by inhaled isoflurane (Abbvie)
and maintained with continuous infusion of propofol 2mL/kg/h (Fresenius), fentanyl 50 µg/kg/h (Kern
Pharma), and diazepam 10 µg/kg/h (Roche). Animals were intubated and ventilated with 100% oxygen
saturation. The animals received 5000 IU of heparin and amiodarone 2 mg/kg/h (Sanofi Aventis) to
avoid blood clotting of catheters and malignant cardiac arrhythmias, respectively. Before balloon
inflation, coronary anatomy was visualized to check for vasculature abnormalities.
Ischemia/reperfusion was induced by LAD occlusion for 45 min, using a JL 3 6F catheter and
an angioplasty balloon (inflated to the pressure of eight atmospheres). In cases when ventricular
fibrillation/ventricular tachycardia occurred, we administered a biphasic DC shock (10–20 joules),
combined with direct manual chest compressions. After 45 min of LAD occlusion, the artery was
unblocked, and after 10 min of reperfusion, APTOLL was administered intravenously in slow bolus at
a dose of 0.078 mg/kg (equivalent dosage previously tested in mice [13]) and diluted in distilled water.
The animals were then randomized to a control group (n = 10) or treated with APTOLL (n = 10).
A total of 10 mL of arterial blood was obtained from the femoral artery at the following times: before
AMI, 50 min, 75 min, 2 h, 8 h, 24 h, 3 days, and 7 days post-AMI. Immediately after collection, plasma
was isolated by centrifugation at 3000 rpm for 10 min and all the samples were kept at −80 ◦C before
experimentation and stored for future investigation.
Overall, 20% of pigs that were treated with a placebo and 10% that were treated with APTOLL
died by day 1 after treatment.
2.3. Echocardiography
Pig hearts were visualized by echocardiography by using a Vivid Q ultrasound system from GE
healthcare (General Electric, Chicago, IL, USA), equipped with a 1.9-4 MHz scan head. In anesthetized
animals, parasternal short-axis-view images of the heart were recorded in a B-mode to allow
M-mode recordings by positioning the cursor in the parasternal short-axis view perpendicular
to the interventricular septum and posterior wall of the left ventricle. From these recordings, the
following parameters were determined using the on-site software cardiac package: systolic and diastolic
interventricular septum thickness (IVS), systolic and diastolic left-ventricle internal diameter (LVID),
systolic and diastolic left-ventricle posterior wall thickness (LVPW), left-ventricle ejection fraction (EF),
left ventricle shortening fraction (FS), heart rate (HR), and cardiac output (CO). In addition, left ventricle
ejection fraction (LVEF) was also measured by using the B-mode Simpson biplane method, using
4 chamber and a 2 chamber left ventricle long axis views, with similar results. To avoid inter-observer
derived biases, data acquisition and analysis was performed by one single operator.
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2.4. Evans Blue/TTC Staining
The extension of myocardial infarction was evaluated by Evans blue perfusion and TTC staining.
By day 7, a catheter inflated at the same position, as in day 0, to avoid Evans blue perfusion downstream
to the area at risk, and a pigtail catheter was inserted from the femoral artery and placed up to the left
ventricle for Evans blue perfusion into the systemic circulation. After 1 min of perfusion, the animals
were sacrificed by injection of a potassium chloride solution, and the hearts were then isolated, washed
three times with saline buffer, frozen for 12 h at –20 ◦C, and chopped into 0.5 cm slices from base to
apex. The slices were incubated with 1% TTC dye, dissolved in a saline buffer for 20 min at 37 ◦C,
and then washed for 20 min with 10% paraformaldehyde. Images were acquired with the ImageJ
software, discriminating between healthy areas (blue) from the area at risk (dark red) and the pale
necrotic area (white), calculating the area of necrosis as percentage respect to the area at risk.
2.5. Confocal Microscopy
Paraffin embedded 0.5 µm heart sections were incubated with anti-MMP-9 (diluted 1:500 in
PBS 1.5% BSA) primary antibody overnight at 4 ◦C. After washing three times with PBS, the slides
were incubated with Alexa-Fluor-647 conjugated secondary antibody for 1 h at room temperature.
Slides were washed three times with PBS and mounted in PBS media, containing Hoechst for nuclei
visualization. Images were taken using a Leica TCS SP5 confocal microscope. At least three different
fields per condition were obtained.
2.6. Determination of Cardiac TroponinI
Plasma Troponin I was determined with the commercial Human Cardiac Troponin 1 SimpleStep
ELISA Kit (Abcam), following the manufacturer’s instructions.
2.7. Histology and Immunohistochemistry
Histological, immunohistochemical, and immunohistofluorescence procedures were performed,
as previously described [19,20].
2.8. Statistical Analysis
All values were given as mean± S.D. Significance i reported at the 5% level. Whenever comparisons
were made with a common control, significance of differences was tested by Dunnett′s modification of
the t-test.
3. Results
3.1. ApTOLL Induces Cardiac Protection in Response to IR
To test the effect of ApTOLL, we first determined cardiac troponin-I levels, indicative of ischemic
injury [21] at the times indicated, detecting a significant reduction 24 h after IR in pigs treated with
0.078 mg/kg ApTOLL vs. Placebo (Figure 1A). Cardiac ultrasound also revealed a significant reduction
of the left ventricle ejection fraction (LVEF) by day 7 in the same pigs (Figure 1B). The rest of the
parameters examined did not show differences, with the exception of the shortening fraction (FS),
which was reduced by day 7 after treatment with ApTOLL (Figure 2, Table 1).
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Figure 1. (A) Cardiac Troponin I (cTnI) levels in plasma collected from pigs treated with 0.078 mg/kg 
ApTOLL or Placebo at 8 and 24 h after ischemia/reperfusion (IR) (N = 10/group, mean ± SD * p < 0.002 
ApTOLL). (B) Left ventricle ejection fraction levels detected by cardiac ultrasound at the times 
indicated. Representative M-Mode images from Placebo and ApTOLL treated animals, in which end 
diastolic and systolic thickness of the interventricular septum thickness (IVS) and left-ventricle 
posterior wall thickness (LVPW) are represented (N = 10/group (d0), N = 9 ApTOLL/8 Placebo (d3, 
and d7). Mean ± SD * p < 0.001 ApTOLL vs. Placebo). 
 
Figure 2. Echocardiographic parameters collected by day 3 (A) and day 7 (B), respectively, after IR. 
(N = 9 ApTOLL/8 Placebo. Mean ± SD. EF: * p < 0.0006 ApTOLL vs. Placebo. FS: * p < 0.003 ApTOLL 
vs. Placebo). 
Figure 1. (A) Cardiac Troponin I (cTnI) levels in plasma collected from pigs treated with 0.078 mg/kg
ApTOLL or Placebo at 8 and 24 h after ischemia/reperfusion (IR) (N = 10/group, mean ± SD * p < 0.002
ApTOLL). (B) Left ventricle ejection fraction levels detected by cardiac ultrasound at the times indicated.
Representative M-Mode images from Placebo and ApTOLL treated animals, in which end diastolic
and systolic thickness of the interventricular septum thickness (IVS) and left-ventricle posterior wall
thickness (LVPW) are represented (N = 10/group (d0), N = 9 ApTOLL/8 Placebo (d3, and d7). Mean± SD
* p < 0.001 ApTOLL vs. Placebo).
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Table 1. Echocardiographic parameters tested by day 3 (D3) and day 7 (D7) after procedure. End
diastolic Interventricular septum thickness (IVSD); end diastolic left ventricle internal diameter (LVIDD);
end diastolic left ventricular posterior wall thickness (LVPWD); end systolic interventricular septum
thickness (IVSS); end systolic left ventricular internal diameter (LVIDS); end systolic left ventricular
posterior wall thickness (LVPWS); left ventricle ejection fraction (LVEF); fractional shortening (FS); heart
rate (HR); cardiac output (CO). * EF: p < 0.001ApTOLL vs. Placebo. FS: p < 0.003 ApTOLL vs. Placebo.
PARAMETER PLACEBO D3 APTOLL D3 PLACEBO D7 APTOLL D7 PARAMETER
IVSD (mm) 11.68 ± 0.806 10.857 ± 0.61 10.124 ± 1.357 11.353 ± 1.276 IVSD (mm)
LVIDD (mm) 37.96 ± 4.219 39.511 ± 4.319 38.488 ± 8.667 38.067 ± 6.052 LVIDD (mm)
LVPWD (mm) 13.430 ± 2.394 9.954 ± 1.746 10.475 ± 0.67 11.093 ± 2.796 LVPWD (mm)
IVSS (mm) 15.77 ± 2.264 13.562 ± 0.932 13.153 ± 2.806 14.177 ± 1.678 IVSS (mm)
LVIDS (mm) 26.28 ± 4.36 29.126 ± 3.493 27.316 ± 5.860 24.705 ± 4.129 LVIDS (mm)
LVPWS (mm) 15.77 ± 3.383 11.024 ± 1.339 10.926 ± 1.704 11.90 ± 1.722 LVPWS
EF (%) 49.07 ± 5.91 46.31 ± 2.60 55.14 ± 4.947 66.85 ± 3.196 * EF (%)
FS (%) 21.25 ± 3.77 20.272 ± 1.443 28.55 ± 2.530 34.75 ± 2.492 * FS (%)
HR (bpm) 99 ± 31.494 111.1O1 ± 27.31 103.444 ± 31.269 91.875 ± 11.849 HR (bpm)
CO (mL/sec) 3614 ± 2068.651 3940.33 ± 1217.115 3801.111 ± 1.826 3918.875 ± 1356 CO (mL/sec)
3.2. ApTOLL Reduces Left Ventricle Necrosis and Fibrosis by Day 7 after IR
We next asked whether ApTOLL-induced improvement of cardiac function was due to preventing
cardiac necrosis. Evans blue/TTC double staining (see methods for details) showed that after 7 days
of treatment, the necrotic area was significantly reduced in the hearts of pigs treated with ApTOLL
(Figure 3A). In the same way, H/E, Masson Trichrome, and Tunel staining of ventricular sections
showed reduced fibrosis, necrosis, and apoptosis in response to ApTOLL (Figure 3B), suggesting the
antagonizing of TLR4, leading to inhibition of the downstream necrotic molecular cascade.
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Figure 3. (A) Evans blue/T C double stai i erformed in 0.5 cm heart sections isolated 7 days after
IR from pigs treated with 0.078 mg/kg ApTOLL of Placebo (N = 9 ApTOLL/8 Placebo. Mean ± SD.
* p < 0.002 Placebo (Vehicle) vs. ApTOLL). (B) Left panels: H/E staining of heart sections from healthy
and necrotic areas of hearts collected from pigs treated with 0.078 mg/kg ApTOLL or Placebo. Middle
Right panel: Masson Trichrome staining of necrotic sections. Right panel. Tunel assay staining of
necrotic sections. N = 5 ApTOLL/4Placebo.
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3.3. APTOLL Inhibits the Expression of MMP-9 by Day 7 after IR
Degradation of the extracellular matrix is a critical step during myocardial remodeling and
repair. Matrix Metalloprotease 9 (MMP-9), a marker of adverse remodeling [22], plays a key role
in this process as it degrades the extracellular matrix components. In pigs treated with ApTOLL,
the expression of MMP-9 by day 7 after IR was significantly reduced by 40%, compared to the Placebo
group, as detected in the same heart sections as before by confocal microscopy immunofluorescence,
with specific anti-MMP-9 antibodies. In the same way, MMP-9 activity assay also revealed a significant
reduction in response to ApTOLL by day 7 after treatment (Figure 4).
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3.4. ApTOLL Reduces the Expression of Pro-Inflammatory Cytokines 7 Days After Reperfusion
To test the effect of antagonizing TLR4, the level of 36 cytokines and chemokines was assessed in
plasma collected 7 days after IR. We evaluated the levels of CCL1, CCL2, MIP1-A-B, CCL5, CD40L,
C5/C5A, CXCL1, CXCL10, CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, INFG, IL1-A, ILI-B, IL-1RA,
IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL16, IL17-A, IL17- E, IL18, IL21, IL27, IL32, MIF, SERPIN-E1,
TNF-A, and TREM-1, detecting significant differences in 24 cytokines (Table 2).
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Table 2. Plasma levels of cytokines differentially expressed 7 days after procedure.
CYTOKINE PLACEBO APTOLL
CCL5 1.108 ± 0.141 0.27 ± 0.070
CXCL1 0.429 ± 0.024 0.105 ± 0.023
CXCL10 1.542 ± 0.237 0.37 ± 0.07
G-CSF 0.372 ± 0.088 0.0732 ± 0.014
GM-CSF 0.261 ± 0.057 0.031 ± 0.009
ICAM-1 0.154 ± 0.030 0.045 ± 0.009
INF-g 0.092 ± 0.019 0
IL1-a 0.255 ± 0.043 0.108 ± 0.018
ILI-b 0.616 ± 0.146 0.047 ± 0.146
IL-IRA 0.193 ± 0.023 0.421 ± 0.123
IL2 0.493 ± 0.074 0.141 ± 0.036
IL5 0.197 ± 0.020 0.014 ± 0.004
IL6 0.309 ± 0.040 0.165 ± 0.043
IL8 0.317 ± 0.042 0.183 ± 0.047
IL12 0.392 ± 0.054 0.213 ± 0.054
IL16 0.306 ± 0.031 0.16 ± 0.046
IL17-A 0.42 ± 0.042 0.109 ± 0.032
IL18 0.311 ± 0.077 0.504 ± 0.116
IL21 0.466 ± 0.074 0.159 ± 0.029
IL27 0.348 ± 0.037 0
MIF 1.359 ± 0.200 0.527 ± 0.089
SERPIN-E1 0.876 ± 0.095 0.454 ± 0.076
TNF-a 0.52 ± 0.040 0.152 ± 0.045
TREM-1 0.4192 ± 0.039 0.105 ± 0.031
In particular, ApTOLL induced chemokine downregulation of CCL5, CXCL1, G-CSF, CXCL10
(Figure 5A), and pro-inflammatory cytokines, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL5, IL6, IL-8, IL-12,
IL-16, IL-17A, IL-18, and TNFα. It is important to highlight IL-1, IL-6, IL-8, and TNF-α for their key
roles in the inflammatory response during an AMI. However, the levels of IL-18 were upregulated
in response to ApTOLL (Figure 5B). ApTOLL also upregulated the levels of IL-1RA (Figure 5C or
D), an anti-inflammatory cytokine, but downregulated the levels of resolving cytokines IL-21, MIF,
SERPIN-E1, and TREM-1 (Figure 5C, together with CD40, ICAM-1, and IL-27 (Figure 5D).
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4. Discussion
In the current work, we show that ApTOLL may represent a novel therapeutic target for the
treatment of AMI. In pigs subjected to IR, the levels of cardiac troponins [23] were reduced 24 h after
administration of ApTOLL, showing a significant improvement of cardiac function by day 7, as a result
of left ventricle prevention of necrosis, including preservation of the extracellular matrix, as shown
by the reduction of MMP-9 expression. Our results point towards the reduction of the expression of
pro-inflammatory cytokines as a mechanism, at least in part, responsible for cardiac protection induced
by ApTOLL.
Others have shown that TLR4 correlates with a bad outcome in AMI [24,25]. Several reports show
a close correlation between TLR4 and the downstream proinflammatory NF-kappa B transcription
factor and ways of inhibition to reduce several inflammatory conditions [9]. However, most results
have been gathered in vitro and in murine models of AMI [26], while this is the first report in which,
by using a brand-new compound against TLR4, a significant response is achieved in a porcine model
of AMI.
Other studies have demonstrated that TLR4 gene silencing reduces the levels of MMP-9 in human
aortic smooth muscle cells in the context of atherosclerosis [27]. Our data show that ApTOLL also
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prevents extracellular matrix degradation, at least by reducing the expression of MMP-9 by day 7 after
IR, indicative of cardiovascular injury.
The role of TLR4 in activating the immune response have been thoroughly explored in recent years.
TLR4 promotes nuclear NF-kB translocation both in MyD88 dependent and independent pathways
and consequently results in the activation of inflammatory pathways and cytokine release [28]. Thus,
we evaluated the release of inflammatory-related cytokines at 7 days post-reperfusion, a time point in
which the anti-inflammatory-resolution phase is about to start, and, still, TLR4 induced inflammation
that was consistently significant [29–32]. As shown here, ApTOLL significantly reduced the levels of
the proinflammatory cytokines implicated in the progression of AMI.
TLR4 increases the levels of IL-1β, IL-6, IL-8, and TNF-α, contributing to inducing cardiac damage
in AMI [31,32], while ApTOLL did the opposite, as evidenced in this work. Therefore, ApTOLL
may help to maintain heart contractility by preventing cardiac cell death during acute myocardial
infarction. In the same way, chemokines that are overexpressed in response to TLR4 and NF-κB [33]
were also inhibited, hence improving heart function by preventing the recruitment and migration of
immune cells.
Resolving cytokines neutralize and regulate latter stages of the inflammatory response [34].
Two important resolving cytokines, such as IL-4 and IL10, were not affected by ApTOLL, while others
in apparent contradiction were downregulated. To fully understand the contribution of ApTOLL in the
resolution of inflammation, further investigations should focus on the effect of ApTOLL at later time
points to evaluate the contribution of neutrophil and macrophage polarization to a resolving stage [35].
Interestingly, the levels of interleukin 1 receptor antagonist (IL-1RA) were upregulated after treatment
with ApTOLL, a cardioprotective molecule that binds to the receptor of IL-1, blocking its activity [36].
The effect of ApTOLL on IL-18 also constitutes a potentially contradictory, since IL-18 is known
to induce a pro-inflammatory environment under several circumstances. However, reports showing
the pro- and anti-inflammatory properties of IL-18 have emerged, since IL18 binds to IL-18 binding
protein (IL-18BP), which mediates IL-37-induced anti-inflammatory effects [37]. Thereby, and besides
limitations, including sample size and species of the study, ApTOLL = induced IL18 expression in
AMI requires additional investigation.
We used a pig model of coronary ischemia/reperfusion rather than using rodent models, which
allows the use of a significant number of individuals at a low economic cost, because the rodent
cardiovascular system differs substantially from humans. However, although the procedure used
in this work resembles the series of events of patients after reperfusion in the cathlab, the cost of
experimentation in these circumstances is rather high when compared to mice, which in the end
becomes a strong limitation of the study. Hence, further investigation is required to fully validate our
results in patients, as other molecular markers have been tested [38], and to evaluate the relevance
of using ApTOLL to prevent the development of the deadly inflammatory response in high-risk
populations, as well as to investigate a long-term effect of ApTOLL in heart failure, which represents a
significant economic burden given the high number of patients worldwide.
5. Conclusions
Blocking the inflammatory response has emerged as one of the main targets to prevent harmful
outcomes after AMI. ApTOLL is a promising new tool to achieve this objective, blocking TLR4, one of
the upstream molecules that trigger the inflammatory response. Preventing the release of inflammatory
cytokines, it is possible to avoid myocardial damage by reducing cardiac fibrosis through prevention of
extracellular matrix degradation and, hence, preserving the ventricular function. Further experiments
must be performed, but our results make ApTOLL a potential tool for future clinical studies in the
onset of AMI.
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